Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines

Combined measles-mumps-rubella (MMR) vaccines produced by GSK (GSK-MMR) and Merck (Merck-MMR) have demonstrated effectiveness and an acceptable safety profile, as documented over decades of post-licensure use in various regions worldwide. In the United States, 2 doses of the MMR vaccine are recommen...

Full description

Bibliographic Details
Main Authors: Md Ahsan Habib, Michael Povey, Giacomo Casabona, Tina Singh, Remon Abu-Elyazeed
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
febrile convulsion
measles-mumps-rubella vaccine
meningism
mmr
safety
Online Access:http://dx.doi.org/10.1080/21645515.2023.2188852

Internet

http://dx.doi.org/10.1080/21645515.2023.2188852

Similar Items